"The Apothecary" & Other Communications

"The Apothecary"

News Items

Health Canada Advisories

Advisories from the last month are listed below.

For older advisories, please consult the appropriate archive.

For Health Professionals:
January 31, 2012 -	VELCADE® (bortezomib): Fatal if Given Intrathecally
January 30, 2012 -	Association of CELEXA® (citalopram hydrobromide) with Dose - Dependent QT Prolongation
January 23, 2012 -	Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ*) or aliskiren/hydrochlorothiazide (RASILEZ HCT*)
December 23, 2011 -	Important Safety Information on the Correct Use of EpiPen® and EpiPen® Jr Auto-Injector
For the Public:
January 30, 2012 -	Association of CELEXA® (citalopram hydrobromide; also marketed as generics) and abnormal heart rhythms
January 23, 2012 -	Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ*) or aliskiren/hydrochlorothiazide (RASILEZ HCT*)
January 19, 2012 -	Champix: Updated safety information for the smoking-cessation drug
January 19, 2012 -	Important Reminder about Weight-loss Health Products
January 13, 2012 -	Novartis Recall of Excedrin Products Extends to Canada
Health Canada Advisories for Health Professionals Archives
Health Canada Advisories for the Public Archives
[Back to Top]